Abstract: The present invention has objects to provide a method for inhibiting the formation of volatile aldehydes and/or the decomposition of fatty acids and use thereof. These objects are attained by establishing a method which comprises incorporating an ?-oligoglucosyl ?,?-trehalose(s) to a target product to inhibit the formation of volatile aldehydes per se and/or the decomposition of fatty acids per se in fatty acid-containing products; an inhibitory agent for inhibiting the formation of volatile aldehydes and/or the decomposition of fatty acids, which contains an ?-oligoglucosyl ?,?-trehalose(s) as an effective ingredient; and use thereof to thereby obtain various compositions such as food products, cosmetics, pharmaceuticals, and their materials and intermediates each having a high quality and stability.

Abstract: A method of preparing a ribofuranose derivative essentially free of pyranose compounds includes a step of contacting a solution of MDR containing MDRP as an impurity in a solvent including methanol and/or tetrahydrofuran with at least one alkali metal periodate under conditions sufficient to oxidize at least a portion of the MDRP. MDR containing at most 5 wt % of MDRP based on the total weight of MDR and MDRP may be produced.

Abstract: Synthetic molecule construct of the structure F—S1—S2-L where F is an O-linked mono-, di-, tri- or oligo-saccharide, S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl, S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—, and L is a diacyl- or dialkyl-glycerophospholipid.

Abstract: The present invention provides a nucleus pulposus filler or the like which is to be packed into an area in deformed intervertebral disc wherein normal nucleus should be located and can be stabley maintained for a long time More preferably, the present invention provides a nucleus pulposus filler comprising a crosslinked chondroitin sulfate as an active ingredient. The photocrosslinked chondroitin sulfate is preferably the following one: a photocrosslinked chondroitin sulfate obtainable by freezing a photoreactive chondroitin sulfate-containing solution comprising: a photoreactive chondroitin sulfate to which a photoreactive group is bound; an aqueous solvent capable of dissolving the photoreactive chondroitin sulfate; and any one substance selected from the group consisting of an alcohol having aqueous solvent miscibility, a surfactant, and a cheleting agent; irradiating the resulting frozen product with light; and then melting the frozen product.

Abstract: The invention relates to a method for producing phosphate-bridged nucleoside conjugates. In the method a nucleophile is first dissolved in a non-aqueous solvent and dried, and a cyclosaligenyl phosphate compound is subsequently added to the solution.

Abstract: Non-crosslinked derivatives of oligo/polysaccharides of formula wherein: X is OH, O?M, NH—R1, O—R1; M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom; Y is H or R2; R1: the residue of an oligo/polysaccharide; R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid; provided that at least one X is NH—R1 or O—R1, while the other two X are present in acid (OH) or salified form (OM).

Abstract: The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent comprising, as an active ingredient, a glycosaminoglycan or a salt thereof that keeps sulfate group and has the characteristics of the following (1) and (2): (1) a basic structure is a disaccharide repeating structure consisting of a hexuronic acid residue and a glucosamine residue, (2) one or less of the position among a 2-position hydroxyl group of a hexuronic acid residue, a 6-position hydroxyl group of a glucosamine residue and a 2-position amino group of the glucosamine residue in the basic structure of the aforementioned (1) does not have the sulfate group.

Abstract: The present invention regards a novel administration form and a novel administration regime useful in the treatment and prevention of a bacterial lung infection in patient in need thereof, in particular by providing a composition useful for aerosolization of a highly concentrated solution of aminoglycosides such as Tobramycin.

Abstract: The invention relates to certain low-molecular weight sulphated polysaccharide derivatives of marine native exopolysaccharides (EPSs) excreted by mesophilic marine bacteria from a deep hydrothermal environment, wherein said derivatives can be obtained by means of a method which comprises a step of free radical depolymerisation of said native EPSs followed by a step of sulphating the resulting depolymerised derivatives. The present invention further relates to the use of said low-molecular weight sulphated polysaccharide derivatives as a wound-healing agent, particularly for preparing pharmaceutical compositions suitable for treating or preventing diseases of the connective tissues and particularly skin and gum tissues. The figure demonstrates how polysaccharide derivative GY 785 DRS according to the invention can stimulate fibroblast proliferation in latticed or reconstructed connective tissues at a concentration of 10 ?g (m) g/ml.

Abstract: A cellulose derivative and a resin composition having good thermoplasticity, strength, and elongation at break and therefore suited to molding processing are provided. The cellulose derivative is derived by replacing at least part of the hydrogen atoms of the hydroxyl groups of cellulose with a hydrocarbon group and an aliphatic or aromatic oxycarbonyl group.

Abstract: Embodiments of the processes provided herein allow for extraction of high quality pectins from pectin-containing plant materials using oxalic acid for extraction of the pectin containing material. Generally described, the process for extracting pectin having a high degree of polymerization includes preparing an aqueous suspension of a pectin-containing plant material; adding oxalic acid and/or a water-soluble oxalate to the aqueous suspension in an amount sufficient to provide a mixture having a pH of between 3.0 and 3.6 and a total molarity of oxalate greater than a total molarity of calcium(II); heating the mixture to a temperature from about 50 to about 80° C. for a time sufficient to extract pectin from the pectin-containing plant material; and separating the extracted pectin from the mixture.

Abstract: We disclose here a method for using Poly-ICLC to prevent and/or treat certain human and veterinary infectious, neoplastic and autoimmune disorders, as well as for regulating a broad variety of genes in humans, consisting of use of poly-ICLC repeatedly and at low doses, alone or in combination with other drugs or vaccines. As such it represents an example of broad spectrum host-targeted therapeutics, in contrast to conventional antibiotics, antiviral or antineoplastic agents that target specific organisms or tumors.

Abstract: A method for producing a ?-enriched protected decitabine comprising: a) coupling a protected 2-deoxy-ribofuranose with a protected 5-azacytosine in the presence of a catalyst to form a reaction mixture comprising the protected decitabine of formula I; and b) quenching the reaction mixture of step a) with a base. The ?-enriched protected decitabine so made may be deprotected to produce a decitabine product in a high yield and purity.

Abstract: This invention pertains to methods for oligonucleotide synthesis, specifically the synthesis of oligonucleotides that contain a high content of guanine monomers. In more detail, the invention relates to a method for coupling a nucleoside phosphoramidite during the synthesis of an oligonucleotide to a universal support, to a first nucleoside, or to an extending oligonucleotide. The invention further relates to oligonucleotides obtainable by the methods of the invention.

Abstract: Provision of a novel combined therapy with ECyd, which therapy exhibits remarkable antitumor effect and gives less adverse effects. The invention provides an antitumor agent containing, in combination, 1-(3-C-ethynyl-?-D-ribopentofuranosyl)cytosine or a salt thereof and carboplatin.

Abstract: The present invention provides a method for purifying cellobiose which comprises the steps of (A) preparing a cellobiose-containing sugar solution; (B) increasing the rate of cellobiose present in the sugar solution relative to the total saccharides present therein up to at least 50% by mass; and (C) crystallizing cellobiose; and a method for preparing cellobiose having a high content of the ?-anomer thereof which comprises the step of drying a cellobiose-containing sugar solution having a rate of cellobiose of at least 90% by mass relative to the total saccharides present therein while maintaining the sugar solution at a temperature ranging from 80 to 95° C. These methods of the present invention permit the economical preparation of cellobiose having considerably improved purity and recovery rate, without using any complicated process. Moreover, the present invention also permits the preparation of cellobiose highly soluble in water.

Abstract: A glyoxal and boron free purified cationic polygalactomannan may be prepared by reacting a polygalactomannan flour, a nonionically derivatized polygalactomannan flour, or a mixture thereof, with a cationising reagent, adjusting the pH to be from about 4 to about 6; cross-linking the cationic with glyoxal, and filtering and water washing the cationic polygalactomannan to produce a glyoxalated purified cationic polygalactomannan containing not more than 70% by weight of water. In some cases it may be desirable to introduce a buffering agent to the glyoxalated purified cationic polygalactomannan to regulate the pH to from 8.0 to about 9.5, when measured at 1% (dry matter) in water. In other cases, it may be desirable to remove water to produce glyoxal free purified cationic polygalactomannan in powder form. Such compounds are particularly useful in personal care products.

Abstract: The present invention relates to a novel crystalline form of a Compound 3,4?,5-trihydroxy-stilbene-3-?-D-glucoside (polydatin) and a method of preparation and use thereof, and to a pharmaceutical composition containing crystalline form I of 3,4?,5-trihydroxy-stilbene-3-?-D-glucoside. Crystalline form I of 3,4?,5-trihydroxy-stilbene-3-?-D-glucoside of the present invention has a stable crystalline morphology, a definite melting point and a good chemical stability. Such a novel form of 3,4?,5-trihydroxy-stilbene-3-?-D-glucoside possesses the properties required for the preparation of solid formulations and is easily tabletable and readily formable when formulated, which allows for substantial decrease in raw materials costs, more facile operations in production and easier control over quality in industrial drug production, and moreover, better convenience in storage.

Abstract: The present invention is related to a hyaluronic acid formulation including a mixture of hyaluronic acids having different weight-average molecular weight and different rheological, tissue scaffold, insulation and degradation properties in aqueous solution. The resulting formulation demonstrated an optimal balance between adhesion, tissue scaffold, insulation and treating time on the treatment and prevention of IBD (inflammatory bowel disease) such as ulcerative colitis and Crohn's disease. Thus, the formulation of the present invention exhibits a quick and lasting effect on the treatment and prevention of duodenal or peptic ulcer and bleeding which is very good thing indeed.

Abstract: A method for inhibiting proliferation of Helicobacter pylori including a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) GlcNAc1-alpha-O—Y ??(1) (in the formula (1), Y is a straight-, branched- or cyclic-aliphatic hydrocarbon group having 1 to 27 carbon atoms or a straight-, branched- or cyclic-acyl group having 1 to 27 carbon atoms). The diet of the food, the beverage or the pharmaceutical preparation comprises the proliferation inhibitor of Helicobacter pylori.